极低卡路里生酮饮食(VLCKD)被广泛用于成功的减肥策略中。在这里,在未服用任何药物的超重和肥胖受试者中,我们评估了VLCKD对非酒精性脂肪性肝病(NAFLD)的疗效和安全性以及通常与该疾病相关的参数.这个未来,现实生活中的研究包括33名随访VLCKD8周的参与者.使用瞬时弹性成像(FibroScan)诊断NAFLD。人体测量数据,生物阻抗分析,并在饮食干预前后收集生化测定。BMI(kg/m2)(从33.84±6.55到30.89±6.38,p<0.01),腰围(cm)(从106.67±15.51到98.64±16.21,p<0.01),VLCKD后,脂肪质量(Kg)(从38.47±12.59到30.98±12.39,p<0.01)显着降低。CAP(db/m),FibroScan参数量化脂肪肝累积,显示VLCKD后显著降低(从266.61±67.96降至223±64.19,p<0.01)。在VLCKD之后,脂肪肝指数(FLI),脂肪变性的基准,也显示了显着下降(从62.82±27.46降至44.09±31.24,p<0.01)。此外,空腹血糖,胰岛素,甘油三酯,总胆固醇,LDL-胆固醇,ALT,γGT,和FT3血液浓度,以及胰岛素抵抗(通过HOMAIR量化)和收缩压和舒张压水平,在VLCKD后显著降低(所有参数p<0.01)。相比之下,HDL-胆固醇,25(OH)维生素D,VLCKD后,FT4血药浓度较高(所有参数p<0.01)。VLCKD后CAP的变化(δ)与本研究中研究的任何其他参数的δ均无相关性。WeconcludedthatVLCKDisahelpfulapproachforNAFLDindependentofchangesinfactorscommonlyassociatedwithNAFLD(obesity,脂肪量,胰岛素抵抗,脂质,和血压)以及维生素D和甲状腺激素水平。
Very low-calorie ketogenic diets (VLCKD) are widely employed in successful weight-loss strategies. Herein, we evaluated the efficacy and safety of a VLCKD on non-alcoholic fatty liver disease (NAFLD) and parameters commonly associated with this condition in overweight and obese subjects who did not take any drugs. This prospective, real-life study included thirty-three participants who followed a VLCKD for 8 weeks. NAFLD was diagnosed using transient elastography (FibroScan). Data on anthropometric measurements, bioimpedance analysis, and biochemical assays were gathered both before and after the dietary intervention. BMI (kg/m2) (from 33.84 ± 6.55 to 30.89 ± 6.38, p < 0.01), waist circumference (cm) (from 106.67 ± 15.51 to 98.64 ± 16.21, p < 0.01), and fat mass (Kg) (from 38.47 ± 12.59 to 30.98 ± 12.39, p < 0.01) were significantly lower after VLCKD. CAP (db/m), the FibroScan parameter quantifying fatty liver accumulation, showed a significant reduction after VLCKD (from 266.61 ± 67.96 to 223 ± 64.19, p < 0.01). After VLCKD, the fatty liver index (FLI), a benchmark of steatosis, also revealed a significant decline (from 62.82 ± 27.46 to 44.09 ± 31.24, p < 0.01). Moreover, fasting blood glucose, insulin, triglycerides, total cholesterol, LDL-cholesterol, ALT, γGT, and FT3 blood concentrations, as well as insulin resistance (quantified by HOMAIR) and systolic and diastolic blood pressure levels, were significantly lower after VLCKD (p < 0.01 for all the parameters). By contrast, HDL-cholesterol, 25 (OH) vitamin D, and FT4 blood concentrations were higher after VLCKD (p < 0.01 for all parameters). The variation (δ) of CAP after VLCKD did not show a correlation with the δ of any other parameter investigated in this study. We conclude that VLCKD is a helpful approach for NAFLD independent of changes in factors commonly associated with NAFLD (obesity, fat mass, insulin resistance, lipids, and blood pressure) as well as vitamin D and thyroid hormone levels.